Single-cell transcriptomics of heterogeneous patient-derived organoids reveals novel therapeutic targets in high-grade serous ovarian cancer
Bisiayo FashemiiD, Yukihide OtaiD, Vijayalaxmi G. GuptaiD, Maia Lina ElizagarayiD, Roger Piqué-RegiiD, Nardhy Gomez‐LopeziD, Mary MulleniD, Dineo KhabeleiD
Abstract
High-grade serous ovarian carcinoma (HGSOC) is characterized by widespread peritoneal dissemination and poor long-term survival, largely driven by metastatic relapse following initial response to chemotherapy. Defining the molecular programs that enable tumor progression from the primary ovarian site to metastatic niches remains a key challenge. Here, we leverage patient-derived organoids (PDOs) coupled with single-cell RNA sequencing (scRNA-seq) to interrogate tumor evolution and identify regulators of metastatic competence in HGSOC. We profiled PDOs and matched formalin-fixed paraffin-embedded (FFPE) tumor samples from ovarian and omental disease sites across seven patients. Single-cell transcriptomic analysis revealed conserved and patient-specific cellular states and enabled reconstruction of inferred trajectories of tumor progression. Comparative trajectory analysis identified gene expression programs associated with metastatic transition from ovarian to omental tumors. Among these, the heparan sulfate proteoglycan AGRIN emerged as a consistently upregulated gene along the metastatic axis. Cell-cell communication analyses suggested that AGRIN-mediated signaling involves both epithelial tumor cells and stromal components, implicating the extracellular matrix in shaping metastatic behavior through mechanotransduction and integrin-associated pathways. Functional validation using genetic depletion of AGRIN in ovarian cancer cell lines demonstrated reduced migratory and invasive capacity, supporting a causal role for AGRIN in promoting metastatic phenotypes. Together, these findings identify AGRIN as a regulator of metastatic competence in HGSOC and highlight extracellular matrix-associated signaling as a key driver of disease progression. More broadly, this study demonstrates that PDO-based single-cell transcriptomic approaches can uncover actionable regulators of metastasis and provide a scalable framework for therapeutic target discovery across cancer types. SignificancePatient-derived organoids analyzed by single-cell transcriptomics reveal dynamic tumor evolution and uncover AGRIN as a regulator of metastatic competence in HGSOC, demonstrating the utility of living tumor models for therapeutic target discovery.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Single cell derived organoids capture the self-renewing subpopulations of metastatic ovarian cancer
Tania Velletri, Emanuele Carlo Villa, … Giuseppe Testa·bioRxiv·Nov 30, 2018
- Multi-modal characterization of transcriptional programs that drive metastatic cascades to solid sites and ascites in ovarian cancer
Kaiyang Zhang, Essi Kahelin, … Sampsa Hautaniemi·bioRxiv·Aug 26, 2025
- Keratin 5 marks cancer-propagating cells sustained by an osteopontin-producing niche in high-grade serous ovarian carcinoma
Mallikarjun Bidarimath, Coulter Q. Ralston, … Alexander Yu. Nikitin·Cancer Heterogeneity and PlasticityPeer-reviewed·Apr 25, 2026
- Tumor landscape of epithelial ovarian cancer highlights that EGR1 drives tumor invasion at single-cell resolution
Yuan-Fu Zhang, Shu Sun, … Qiuyan Guo·bioRxiv·Jul 26, 2022
- A TEMPORAL MODEL OF TUMOR-IMMUNE DYNAMICS IN HIGH GRADE SEROUS OVARIAN CANCER
Donagh Egan, Kate Glennon, … Donal J. Brennan·npj Precision OncologyPeer-reviewed·Jun 16, 2025
- Cancer stem cell transcriptomic signatures reveal patient-to-patient heterogeneity emphasizing the need for patient-specific ovarian cancer targets
Matthew S. Jung, Lindsey J. Davis, … Rachel S. Perkins·bioRxiv·Oct 2, 2026